Form 8-K - Current report:
SEC Accession No. 0001367644-22-000135
Filing Date
2022-09-26
Accepted
2022-09-26 17:05:55
Documents
17
Period of Report
2022-09-26
Items
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ebs-20220926.htm   iXBRL 8-K 38805
2 EX-99.1 emergent092622disclosure.htm EX-99.1 9606
7 GRAPHIC emergent092622disclosure001.jpg GRAPHIC 214157
8 GRAPHIC emergent092622disclosure002.jpg GRAPHIC 294404
9 GRAPHIC emergent092622disclosure003.jpg GRAPHIC 60014
  Complete submission text file 0001367644-22-000135.txt   990275

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ebs-20220926.xsd EX-101.SCH 2218
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ebs-20220926_def.xml EX-101.DEF 2933
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ebs-20220926_lab.xml EX-101.LAB 27198
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ebs-20220926_pre.xml EX-101.PRE 14705
11 EXTRACTED XBRL INSTANCE DOCUMENT ebs-20220926_htm.xml XML 11025
Mailing Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879
Business Address 400 PROFESSIONAL DR, SUITE 400 GAITHERSBURG MD 20879 240-631-3200
Emergent BioSolutions Inc. (Filer) CIK: 0001367644 (see all company filings)

EIN.: 141902018 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33137 | Film No.: 221266525
SIC: 2834 Pharmaceutical Preparations